### **Overview** Nectar Lifesciences Limited (NLL) is an integrated, globally focused pharmaceutical company founded in 1995 and headquartered in Chandigarh, India. The company specializes in the research, development, and manufacturing of **cephalosporin-based antibiotics** — specifically from the second to fourth generations — across **Active Pharmaceutical Ingredients (APIs)**, **Finished Dosage Forms (FDF)**, and niche **menthol and mint derivatives**. It operates through a vertically integrated model with manufacturing facilities in **Punjab, Himachal Pradesh, and Jammu & Kashmir**, serving over **60 countries** worldwide. NLL is listed on the **BSE and NSE** in India, with **Global Depositary Receipts (GDRs)** listed on the **Luxembourg Stock Exchange**, reflecting its international investor base and strategic global footprint. --- ### **Business Segments & Capabilities** #### **1. Cephalosporin API Manufacturing (Core Strength)** NLL is a **global leader in cephalosporin API production**, holding **world’s largest production capacity** for key molecules: - **Cefixime Trihydrate** - **Cefuroxime Axetil (amorphous & crystalline)** - **Cefpodoxime Proxetil** - **Cefotaxime Sodium** - **Ceftriaxone Sodium** The company operates **11–14 advanced manufacturing facilities** across **Unit 1 and Unit 2 (Derabassi, Punjab)**, including one of **Asia’s most advanced sterile manufacturing facilities**, designed for **minimal human intervention** and compliance with the highest global regulatory standards. - **Annual API capacity**: Over **2,000 metric tons** - **Multi-purpose facilities**: All plants are reconfigurable based on demand, ensuring operational flexibility. - **Regulatory approvals**: USFDA, EU GMP (INFARMED), PMDA (Japan), KFDA (Korea), ANVISA (Brazil), COFEPRIS (Mexico), MCC (South Africa), and others. - **Unique technical edge**: One of the few Indian companies with **both lyophilization and crystallization capabilities**, enhancing process control and product quality. - **Cross-contamination control**: Features **dedicated production units with isolated finishing suites** and a **Single Machine Single Room (SMSR)** design in its capsule unit. NLL has filed **44 Drug Master Files (DMFs)** globally and holds a strong regulatory portfolio, including submissions in the US, EU, Japan, and South Africa. --- #### **2. Finished Dosage Formulations (FDF)** NLL is strategically shifting toward an **FDF-focused business model** to drive sustainable growth and higher-margin revenue. The company operates a **state-of-the-art FDF facility in Baddi, Himachal Pradesh**, covering over **5 acres**, and featuring: - Minimal human intervention - Serialization-enabled packaging for export compliance - Compliance with **USFDA, EDQM, MHRA, MCC, ANVISA, and OGYI (Hungary)** **Annual FDF Capacity:** - **180 million tablets** - **180 million sterile capsules** - **24–240 million injectable vials** - **10.5 million dry syrups/oral suspensions** - **3,000 kg granules** **Market Focus:** - Exports dominate, targeting **Southeast Asia, Latin America, CIS, Africa, and EU** - Successfully filed **two major cephalosporin FDF dossiers in Europe** (commercialization began FY21), with **10 more MAs planned** - Supplies regulated, high-end emerging markets; limited domestic FDF presence due to India's FDC regulatory environment --- #### **3. Menthol & Mint Derivatives Business** NLL has established a **differentiated, premium position** in the **pharmaceutical-grade menthol** space, leveraging its pharmaceutical expertise in a largely unorganized market. - Operates **state-of-the-art facilities in North India** compliant with **GMP standards** - First company globally to file a **US DMF for Natural Menthol** - Global-scale processing capacity with strong EHS and quality systems - Temporarily scaled down operations (since 2023) to **upgrade technology and reposition the business** toward **value-added, specialty products** rather than commoditized offerings - Plans to relaunch **premium menthol products** with enhanced differentiation --- #### **4. Empty Hard Gelatin Capsules (EHGC)** NLL is among the **top 5 EHGC manufacturers in India**, operating a **4 billion capsules/year** facility, the only one in India with the **SMSR concept** to minimize contamination risk. - Products: Two-piece, double-lock gelatin capsules, sizes 0, Oel, 1, 2, 3 - Key features: **5-year shelf life, ethylene oxide-free, BSE/TSE-free, Halal-certified** - Innovations: Launched **Nexxicap Minty™** (menthol-infused) and **Nexxicap Pearl™** (pearl-colored capsules) - GMP-certified by **USFDA and EDQM**; DMF filed internationally --- ### **Global Footprint & Market Presence** - **Exports to over 60 countries**, with **~45 countries** actively served across APIs and FDFs - Key markets: **EU, Asia-Pacific, Latin America (Brazil, Mexico), CIS, Africa** - Subsidiaries: **Nectar Lifesciences UK Limited** and **Nectar PT Unipessoal LDA (Portugal)** — used for IP holding and EU market access - Member of **Pharmexcil (Pharmaceutical Export Promotion Council of India)** --- ### **Growth Strategy & Transformation (2022–2025)** NLL is executing a **strategic transformation** from an **API-dominant** to a **formulation-led, vertically integrated player**. Key elements include: | Strategic Pillar | Details | |------------------|--------| | **Vertical Integration** | In-house API + FDF integration to improve cost efficiency, margins, and regulatory control | | **FDF Focus** | Increasing share of formulations in revenue; targeting regulated and high-growth emerging markets | | **R&D Investment** | Developing **new-generation cephalosporins**, complex injectables, and delivery systems | | **Capacity Expansion** | Equipment realignment and marginal augmentation to meet rising global demand | | **Geographic Expansion** | Targeting **EU, Brazil, Mexico, Japan, Korea, China, Africa** with new product filings | | **Operational Excellence** | Implemented **Six Sigma, Kaizen**, solvent recovery, and automation to reduce costs | | **Sustainability & ESG** | Focus on energy efficiency (12MW captive power plant), EHS compliance, and reduced supply chain risk | --- ### **Leadership & Governance** - **Founder & Managing Director**: **Mr. Sanjiv Goyal** (Commerce & Law graduate), leading since inception in 1995 - **Director (Operations)**: **Mr. Puneet Sud** (IIT BHU, Chemical Engineering), joined 2021; 34 years of API manufacturing experience - **Board-approved financial statements as of July 7, 2025** - Employee strength: **Hundreds to thousands** of highly skilled professionals across technical, regulatory, and R&D roles --- ### **Key Competitive Advantages** 1. **Global leadership in high-demand cephalosporin APIs** 2. **Vertical integration from API to FDF** 3. **Extensive regulatory approvals across major markets** 4. **Flexible, multi-purpose, sterile manufacturing capabilities** 5. **Strong cost structure** due to automation, solvent recovery, and Indian manufacturing base 6. **Commitment to R&D, quality, and sustainability** 7. **First-mover and IP leadership in pharmaceutical-grade menthol** --- ### **Recognition & Awards** - Ranked **#119** in *Fortune India Next 500* (2015) - **#412** in *Fortune India 500* (2019) - **Top 40 biopharma company in Asia-Pacific** (*Bio-Spectrum Asia Pacific*, 2016) - **Outstanding Export Performance Award** (Pharmexcil, 2019) - **Best Strategic Partner Award** (Unilab, Philippines, two years consecutively) ---